Halozyme Therapeutics (HALO) Tops Q3 EPS by 31c, provides guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $100.67 -1.1%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $1.27, $0.31 better than the analyst estimate of $0.96. Revenue for the quarter came in at $290 million versus the consensus estimate of $251.06 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $4.00-$4.20, versus the consensus of $3.96. Halozyme Therapeutics sees FY2024 revenue of $900-1020 million, versus the consensus of $983.9 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Metalla Royalty & Streaming Ltd. (MTA) Reports In-Line Q2 EPS
- Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
